These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 27858268

  • 1. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
    Montgomery ET, Mensch B, Musara P, Hartmann M, Woeber K, Etima J, van der Straten A.
    AIDS Behav; 2017 Feb; 21(2):481-491. PubMed ID: 27858268
    [Abstract] [Full Text] [Related]

  • 2. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
    Mensch BS, Brown ER, Liu K, Marrazzo J, Chirenje ZM, Gomez K, Piper J, Patterson K, van der Straten A.
    AIDS Behav; 2016 Nov; 20(11):2654-2661. PubMed ID: 26906023
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Disclosure of pharmacokinetic drug results to understand nonadherence.
    van der Straten A, Montgomery ET, Musara P, Etima J, Naidoo S, Laborde N, Hartmann M, Levy L, Bennie T, Cheng H, Piper J, Grossman CI, Marrazzo J, Mensch B, Microbicide Trials Network-003D Study Team.
    AIDS; 2015 Oct 23; 29(16):2161-71. PubMed ID: 26544581
    [Abstract] [Full Text] [Related]

  • 5. Sharing of Investigational Drug Among Participants in the Voice Trial.
    Moodley J, Naidoo S, Moodley J, Ramjee G.
    AIDS Behav; 2016 Nov 23; 20(11):2709-2714. PubMed ID: 27146827
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe.
    Musara P, Montgomery ET, Mgodi NM, Woeber K, Akello CA, Hartmann M, Cheng H, Levy L, Katz A, Grossman CI, Chirenje ZM, van der Straten A, Mensch B, Microbicide Trials Network-003D Study Team.
    AIDS Behav; 2018 Mar 23; 22(3):877-886. PubMed ID: 28110473
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence.
    Katz AWK, Mensch BS, Woeber K, Musara P, Etima J, van der Straten A.
    BMC Womens Health; 2019 Jan 25; 19(1):18. PubMed ID: 30683103
    [Abstract] [Full Text] [Related]

  • 10. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
    Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, Nakabiito C, Hoesley C, Justman J, Soto-Torres L, Patterson K, Gomez K, Hendrix CW.
    AIDS Behav; 2013 Feb 25; 17(2):737-47. PubMed ID: 23065145
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
    van der Straten A, Stadler J, Luecke E, Laborde N, Hartmann M, Montgomery ET, VOICE-C Study Team.
    J Int AIDS Soc; 2014 Feb 25; 17(3 Suppl 2):19146. PubMed ID: 25224610
    [Abstract] [Full Text] [Related]

  • 14. Prevention, Partners, and Power Imbalances: Women's Views on How Male Partners Affected Their Adherence to Vaginal Microbicide Gels During HIV Prevention Trials in Africa.
    Miller L, Morar N, Kapiga S, Ramjee G, Hayes R.
    J Acquir Immune Defic Syndr; 2020 Dec 01; 85(4):458-465. PubMed ID: 33136745
    [Abstract] [Full Text] [Related]

  • 15. Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".
    Montgomery ET, van der Straten A, Stadler J, Hartmann M, Magazi B, Mathebula F, Laborde N, Soto-Torres L.
    AIDS Behav; 2015 May 01; 19(5):784-93. PubMed ID: 25416076
    [Abstract] [Full Text] [Related]

  • 16. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study).
    Ngure K, Friedland BA, Szydlo DW, Roberts ST, Garcia M, Levy L, Akello CA, Reddy K, Palanee-Phillips T, Macdonald P, Siziba B, Soto-Torres L, Hosek S, Hillier SL, Nair G, Celum C, van der Straten A.
    PLoS One; 2023 May 01; 18(6):e0287525. PubMed ID: 37352296
    [Abstract] [Full Text] [Related]

  • 17. Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe.
    Young AM, Stoner MCD, Mathebula F, Mohuba R, Baez A, Seyama L, Mutero P, Etima J, Fabiano Z, Fairlie L, Mayo AJ, Balkus JE, Song M, Bunge K, Piper J, Balan IC, van der Straten A, Montgomery ET.
    AIDS Behav; 2024 Nov 01; 28(11):3615-3628. PubMed ID: 39052199
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.